Coreline Soft and Optellum Announce Intent to Collaborate on AI-Enabled Lung Nodule Care

Optellum and Coreline Soft today announced their intent to collaborate across geographies and multiple disease areas to advance AI-enabled lung cancer care across the lung nodule pathway.

Under the proposed collaboration, Optellum would make Coreline Soft's FDA-cleared computer-aided detection (CADe) software for lung nodules, AVIEW Lung Nodule CAD, available through LungOS^®, Optellum's end-to-end AI-powered platform for thoracic care. The proposed collaboration is intended to connect Coreline Soft's FDA-cleared image-based CADe capability with Optellum's CADx, risk assessment, and care management workflow, supporting a more integrated pathway from detection to prioritization and follow-up.

Lung cancer remains one of the world's most urgent healthcare challenges, with outcomes strongly linked to how early the disease is diagnosed and treated. In the US, five-year relative survival is approximately seven times higher when lung cancer is diagnosed at a localized stage than after distant spread (approximately 64% compared with 9%).^[1] At the same time, nearly 20 million chest CT examinations are performed annually in the US, with lung nodules incidentally detected by CT in more than 1.6 million people each year.^[2,3] Almost 10% of the nodules measuring more than 8 mm are likely to be malignant, with many others deemed indeterminate.^[4] Through this collaboration, Optellum and Coreline Soft aim to support clinicians and health systems with a more connected approach to finding, prioritizing, and managing these lung nodule patients, helping enable earlier assessment and timely intervention.

"Optellum is building LungOS^® into a unified operating system for lung cancer and thoracic care more broadly," said Dr. Johnathan Watkins, CEO of Optellum. "Our intended collaboration with Coreline Soft reflects a shared commitment to giving clinicians and health systems the tools they need to support earlier, more confident lung nodule assessment. Coreline Soft's commitment to clinical rigor and combined excellence has underpinned its strong track record in AI-enabled nodule detection. This is highly complementary to Optellum's leadership in reimbursed nodule risk assessment and management. Together, we aim to support a future where no lung nodule patient is left behind."

Coreline Soft's AVIEW Lung Nodule CAD is FDA-cleared CADe software designed to assist radiologists in detecting lung nodules during review of chest CT examinations. The software supports radiologists in the review of chest CT images.

"Coreline Soft has been committed to advancing AI technologies that support radiologists, pulmonologists, and multidisciplinary care teams in lung cancer care," said Jin Kook Kim, CEO of Coreline Soft. "We are pleased to explore this potential collaboration with Optellum. Optellum's LungOS platform and Virtual Nodule Clinic help healthcare institutions manage the care pathway for patients with lung nodules in a more structured way."

"Through this collaboration, we expect to connect Coreline Soft's accumulated expertise in chest CT-based lung nodule detection and lung cancer screening workflow with Optellum's lung nodule risk assessment and management workflow," he added. "Together, we aim to contribute to a more connected, efficient, and scalable lung cancer care model."

The LungOS^® platform for opportunistic screening of incidental lung nodules includes Optellum Virtual Nodule Clinic^® with Patient Discovery AI and reimbursed Lung Cancer Prediction AI, supporting clinicians in identifying, risk-stratifying, and managing patients with lung nodules. Optellum VNC is cleared in the US and Australia for incidental lung nodules, as well as for screening-detected and incidental lung nodules in the EU, UK, and Switzerland.